Werbung

Secarna Pharmaceuticals GmbH & Co. KG

© IZB Innovations- und Gründerzentrum Biotechnologie

Secarna Pharmaceuticals is the leading independent European antisense oligonucleotide (ASO) drug discovery and development company. Secarna’s mission is to leverage its proprietary LNAplus™ antisense oligonucleotide discovery platform to discover, research and develop highly specific, safe, and efficacious antisense therapies for indications in which antisense-based approaches have clear benefits over other therapeutic approaches. Combining technical excellence with antisense drug discovery and development expertise supported by a global network of highly recognized KOLs, Secarna is paving the path for a new generation of ASO therapeutics.


Secarna Pharmaceuticals at a glance:

 

Field of Activity Discovery and development of highly specific, safety-optimized and efficacious 3rd generation ASOs. With in-house programs up to pre-clinical proof-of-concept and in partnerships with pharma and biotech companies in pre-clinical and clinical development, Secarna addresses high unmet medical needs in the areas of oncology/immuno-oncology, immunology, as well as inflammatory, fibrotic, neurodegenerative and cardiometabolic diseases. The Company has built a rich, multifaceted pipeline of innovative ASO therapies in various stages of pre-clinical and clinical development.
Ownership Structure and Financing Privately held.
Partners Secarna’s LNAplusTM platform and ASOs have been validated by in-house projects and in collaborations with top tier industry as well as academic partners. Partnerships include Achilles Therapeutics, Denali Therapeutics, Inc., Firebrand Therapeutics, Inc., the First Affiliated Hospital at Guangzhou Sun Yat-sen University (SYSU) and Lipigon Pharmaceuticals AB. In addition, Secarna has a strategic partnership with Evotec SE, in which the companies have recently achieved program designation in a neuroscience collaboration with Bristol Myers Squibb.
Unique Selling Point Secarna’s proprietary 3rd generation ASO platform LNAplusTM – the only independent ASO platform – encompasses all aspects of drug discovery and pre-clinical development and is proven to be fast, reliable, scalable, efficient at developing a uniquely integrated workflow. The platform includes the powerful proprietary OligofyerTM bioinformatics and LNA Vit(r)oxTM screening system, best-in-class high throughput screening, and target-specific functional assays. Secarna seeks to establish ASO therapeutics as the third pillar in drug development, next to small molecules and antibodies, and expand the universe of druggable targets.
Date of Incorporation/Number of Employees 2015/17

 


Contact:

Alexander Gebauer, MD, PhD, CEO & Managing Director

 

Address Am Klopferspitz 19
82152 Planegg/Martinsried
Telephone +49 89 215 46 375/ 385
E-Mail info@secarna.com
Web-Address www.secarna.com
Social Media LinkedIn